Dr. Nicholas J. Dibella

Hematology
1700 S Potomac St, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 5 Trials
1700 S Potomac St, 
Aurora, CO 

Overview

Nicholas Dibella is a Hematologist practicing medicine in Aurora, Colorado.

His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Multiple Myeloma, Hairy Cell Leukemia (HCL), Endoscopy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 98 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1700 S Potomac St, Aurora, CO 80012

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

98 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other
Study Phase: Early Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 5 Less Clinical Trials

3 Total Publications

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 02, 2017
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

University Of Colorado Hospital

1665 Aurora Ct, 
Aurora, CO 
 (4.0 miles away)
720-848-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manali Kamdar is a Hematologist practicing medicine in Aurora, Colorado. Dr. Kamdar is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kamdar is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

University Of Colorado Hospital

12605 E 16th Ave, 
Aurora, CO 
 (4.0 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Pollyea is a Hematologist practicing medicine in Aurora, Colorado. Dr. Pollyea is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Pollyea is currently accepting new patients.

Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Expertise in
13
conditions
Dr. Rajeev Vibhakar
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (3.9 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rajeev Vibhakar is a Hematologist and an Oncologist practicing medicine in Aurora, Colorado. Dr. Vibhakar is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Gliomatosis Cerebri. Dr. Vibhakar is currently accepting new patients.

Frequently Asked Questions about Dr. Nicholas J. Dibella

How do I make an appointment with Dr. Nicholas J. Dibella?

You can book an appointment with Dr. Nicholas J. Dibella by calling their office at 303-418-7600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nicholas J. Dibella a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nicholas J. Dibella is classified as an Experienced expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nicholas J. Dibella specialize in?

While Dr. Nicholas J. Dibella is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Multiple Myeloma, and Hairy Cell Leukemia (HCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nicholas J. Dibella participate in research or clinical trials?

Yes. Dr. Nicholas J. Dibella has published 3 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Nicholas J. Dibella's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nicholas J. Dibella accept my insurance?

Dr. Nicholas J. Dibella accepts most major insurance plans, including UnitedHealthcare. We recommend calling the office directly at 303-418-7600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dibella's expertise for a condition
ConditionClose
        View All 17 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile